Target Audience | This educational activity is intended for hematologists, oncologists, oncology specialist nurses, and other allied healthcare professionals interested in the management of hematologic malignancies.
|
Accreditation Statement | This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Postgraduate Institute for Medicine (PIM) and prIME Oncology. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.
|
Credit Designation Statement | Postgraduate Institute for Medicine designates this educational activity for a maximum of 4.75 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
|
 Method of Participation | There are no fees for participating and receiving CME credit for this activity. During the period April 2010 through April 30, 2011, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-test by recording the best answer to each question; 4) complete the evaluation form. A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or better.
You may complete the post-test online at www.cmeuniversity.com. Click on “FIND POST-TEST/EVALUATION BY COURSE” on the navigation menu, and search by Course ID 6695. Upon successfully completing the post-test and evaluation, your certificate will be made available immediately.
Estimated time to complete activity: 4.75 hours
|
Disclosure of Unlabeled Use | This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration (FDA). Postgraduate Institute for Medicine; prIME Oncology; Allos Therapeutics, Inc.; Bristol-Myers Squibb; Celgene Corporation; Millennium, The Takeda Oncology Company; and Novartis Oncology do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM; prIME Oncology; Allos Therapeutics, Inc.; Bristol-Myers Squibb; Celgene Corporation; Millennium, The Takeda Oncology Company; and Novartis Oncology. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
|
Disclaimer | Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
|
|
|
Educational Objectives | Upon completion of this educational activity, participants should be better able to:
- Describe the latest management approaches for hematologic malignancies including leukemia, lymphoma, multiple myeloma, myelodysplastic syndromes, and myeloproliferative neoplasms.
- Explain difficult or unusual problems encountered by the practicing hematologist/oncologist.
- Identify appropriate management options based on emerging data.
- Discuss issues surrounding the design and conduct of clinical trials that incorporate novel agents and/or regimens for patients with hematologic malignancies.
- Outline emerging data in the management of multiple hematologic malignancies.
- Explain how to integrate new findings into clinical practice.
|
Program | Multiple Myeloma: Front-Line Therapy
Kenneth C. Anderson, MD
Dana-Farber Cancer Institute, Boston, MA
Multiple Myeloma: Relapsed/Refractory
Kenneth C. Anderson, MD
Dana-Farber Cancer Institute, Boston, MA
Indolent Non-Hodgkin Lymphoma
Julie Vose, MD
University of Nebraska, Omaha, NE
Aggressive Non-Hodgkin Lymphoma
John P. Leonard, MD
Weill Medical College of Cornell University, New York, NY
Hodgkin Disease
Philip Bierman, MD
University of Nebraska, Omaha, NE
Chronic Myelogenous Leukemia
Jorge Cortes, MD
M. D. Anderson Cancer Center, Houston, TX
Chronic Lymphocytic Leukemia
Susan O’Brien, MD
M. D. Anderson Cancer Center, Houston, TX
Myelodysplastic Syndromes
Guillermo Garcia-Manero, MD
M. D. Anderson Cancer Center, Houston, TX
Myeloproliferative Neoplasms
Ayalew Tefferi, MD
Mayo Clinic, Rochester, MN
Acute Leukemia
Wendy Stock, MD
University of Chicago, Chicago, IL
|
Statement of Need | As the rate at which clinical data are released increases and the numbers of therapeutic options grow, it is important for practicing oncologists and hematologists to stay abreast of these advances. Many community oncologists, hematologists, and other physicians involved in the management of hematologic malignancies do not attend major society meetings and, likewise, those who do, find the size and scope to be so broad and intensive that they require summaries of important data for ease of application to their daily practices. In order for rapid clinical progress to have a direct and immediate impact on patients’ lives, the newest findings must be readily applied by the practices of community oncologists and hematologists. In addition, the data presented at large clinical conferences are typically not framed in the context of the clinical practice of community oncologists/hematologists. prIME Oncology presents “Hematologic Malignancies Demystified: The Series—A Critical Appraisal of Data from 2009 and ASH,” to review, summarize, and interpret the most clinically significant data released in 2009 in an effort to meet this need.
|
Disclosure of Conflicts of Interest | Postgraduate Institute for Medicine requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by PIM for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Dr Anderson has disclosed that he has received consulting fees from Celgene Corporation; MERCK & CO., Inc.; Millennium, The Takeda Oncology Company; Novartis Pharmaceuticals Corporation; and Onyx Pharmaceuticals Inc. None of these relationships will impact his ability to present an unbiased presentation. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Bierman has disclosed that he has no real or apparent conflicts of interest to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Cortes has disclosed that he performs contracted research for Bristol-Myers Squibb Company; Novartis Pharmaceuticals Corporation; and Wyeth Pharmaceuticals, Inc. None of these relationships will impact his ability to present an unbiased presentation. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Garcia-Manero has disclosed that he has no real or apparent conflicts of interest to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Kantarjian has disclosed that he has performed contracted research for Bristol-Myers Squibb Company; Genzyme Corporation; and Novartis Pharmaceuticals Corporation. None of these relationships will impact his ability to present an unbiased presentation. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Leonard has disclosed that he has received consulting fees from Biogen Idec Inc; Biotest; Calistoga Pharmaceuticals; Celgene Corporation; Cell Therapeutics, Inc.; EMD Serono, Inc.; Enzon Pharmaceuticals, Inc.; Genentech BioOncology; GlaxoSmithKline; Gloucester Pharmaceuticals, Inc.; Immunomedics, Inc.; Intellikine; Johnson & Johnson; Millennium Pharmaceuticals, Inc., The Takeda Oncology Company; Novartis Pharmaceuticals Corporation; Pfizer Inc; and sanofi-aventis. None of these relationships will impact his ability to present an unbiased presentation. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr O’Brien has disclosed that she performs contracted research for Biogen Idec Inc; Bristol-Myers Squibb Company; Eli Lilly and Company; Genentech BioOncology; Novartis Pharmaceuticals Corporation; Berlex Laboratories, Inc.; Gemin X; Genta Incorporated; and Hana BioSciences. She has also received consulting fees from Allos Therapeutics, Inc.; Celgene Corporation; Facet Biotech; Genmab A/S; GlaxoSmithKline; sanofi-aventis; Sunesis Pharmaceuticals, Inc.; and Trubion Pharmaceuticals Inc. None of these relationships will impact her ability to present an unbiased presentation. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Dr Stock has disclosed that she has received consulting fees from Genzyme Corporation. This relationship will not impact her ability to present an unbiased presentation. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Dr Tefferi has disclosed that he has no real or apparent conflicts of interest to report. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Vose has disclosed that she performs contracted research for Allos Therapeutics, Inc.; AnorMed, Inc.; Applied Molecular Evolution, Inc.; Astellas Pharmaceuticals; Bristol-Myers Squibb Company; Celgene Corporation; Genentech BioOncology; Genzyme Corporation; GlaxoSmithKline; Millennium, The Takeda Oncology Company; Novartis Pharmaceuticals Corporation; Pharmacyclics; and Rigel Pharmaceuticals, Inc. None of these relationships will impact her ability to present an unbiased presentation. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
The employees of Postgraduate Institute for Medicine have disclosed:
- Jan Hixon, RN, BSN, MA – no real or apparent conflicts of interest
- Trace Hutchison, PharmD – no real or apparent conflicts of interest
- Julia Kimball, RN, BSN – no real or apparent conflicts of interest
- Samantha Mattiucci, PharmD – no real or apparent conflicts of interest
- Jan Schultz, RN, MSN, CCMEP – no real or apparent conflicts of interest
The employees of prIME Oncology have disclosed:
- Michael Checkoway (project manager)– no real or apparent conflicts of interest
- Nathan J. Kelly, PhD (clinical) – no real or apparent conflicts of interest
- Trudy Stoddert, ELS (editorial) – no real or apparent conflicts of interest
|
|
Webcast | Click here to view the Webcast
To participate in this activity, your computer should have a processor the equivalent of Intel Pentium II 450 MHz or faster, with 128MB of RAM and a connection to the internet.
|
|
|
|
Webcast | Scroll Down to View this Webcast
The content of this presentation is derived from a live symposium held February 13, 2010, in Houston, Texas.
|
Sponsorship | This activity is jointly sponsored by Postgraduate Institute for Medicine and prIME Oncology.
|
Contact | For questions regarding this activity, please contact:
Postgraduate Institute of Medicine
367 Inverness Parkway
Englewood, Colorado 80112
303-799-1930
information@pimed.com
|
|
